ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P22607


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name FGFR3_HUMAN
Primary accession number P22607
Secondary accession numbers Q14308 Q16294 Q16608
Integrated into Swiss-Prot on August 1, 1991
Sequence was last modified on August 1, 1991 (Sequence version 1)
Annotations were last modified on    June 16, 2009 (Entry version 130)
Name and origin of the protein
Protein name Fibroblast growth factor receptor 3 [Precursor]
Synonyms FGFR-3
EC 2.7.10.1
CD333 antigen
Gene name
Name: FGFR3
Synonyms: JTK4
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
DOI=10.1073/pnas.88.4.1095; PubMed=1847508 [NCBI, ExPASy, EBI, Israel, Japan]
Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
"Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.";
Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
DOI=10.1006/mcbr.2001.0306; PubMed=11703096 [NCBI, ExPASy, EBI, Israel, Japan]
Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H., Kurokawa-Seo M.;
"Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs.";
Mol. Cell Biol. Res. Commun. 4:365-373(2001).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384; THR-441; THR-717 AND PHE-726.
NIEHS SNPs program;
Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
[4]
NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE SPECIFICITY.
TISSUE=Fetal brain;
DOI=10.1016/0888-7543(91)90041-C; PubMed=1664411 [NCBI, ExPASy, EBI, Israel, Japan]
Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F., Housman D.E., Wasmuth J.J.;
"A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4.";
Genomics 11:1133-1142(1991).
[5]
NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
DOI=10.1073/pnas.87.22.8913; PubMed=2247464 [NCBI, ExPASy, EBI, Israel, Japan]
Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
"Putative tyrosine kinases expressed in K-562 human leukemia cells.";
Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
[6]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
TISSUE=Colon tumor;
PubMed=7923141 [NCBI, ExPASy, EBI, Israel, Japan]
Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
"Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
Cancer Res. 54:5206-5211(1994).
[7]
NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
TISSUE=Keratinocyte;
DOI=10.1016/0167-4781(95)00156-B; PubMed=7495869 [NCBI, ExPASy, EBI, Israel, Japan]
Scotet E., Houssaint E.;
"The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific.";
Biochim. Biophys. Acta 1264:238-242(1995).
[8]
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1.
DOI=10.1073/pnas.0307287101; PubMed=14732692 [NCBI, ExPASy, EBI, Israel, Japan]
Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
"Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.";
Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
[9]
VARIANT ACH ARG-380.
DOI=10.1038/371252a0; PubMed=8078586 [NCBI, ExPASy, EBI, Israel, Japan]
Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M., Maroteaux P., le Merrer M., Munnich A.;
"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.";
Nature 371:252-254(1994).
[10]
VARIANT ACH ARG-380.
PubMed=7847369 [NCBI, ExPASy, EBI, Israel, Japan]
Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A., Machado M., Kaitila I., McIntosh I., Francomano C.A.;
"Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
Am. J. Hum. Genet. 56:368-373(1995).
[11]
VARIANT ACH CYS-375.
DOI=10.1007/s004310050278; PubMed=7758520 [NCBI, ExPASy, EBI, Israel, Japan]
Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A., Gitzelmann R., Steinmann B.;
"A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia.";
Eur. J. Pediatr. 154:215-219(1995).
[12]
VARIANT TD CYS-249.
DOI=10.1093/hmg/4.11.2175; PubMed=8589699 [NCBI, ExPASy, EBI, Israel, Japan]
Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R., Wasmuth J.J.;
"Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I.";
Hum. Mol. Genet. 4:2175-2177(1995).
[13]
VARIANTS TD CYS-248; CYS-371 AND GLU-650.
DOI=10.1038/ng0395-321; PubMed=7773297 [NCBI, ExPASy, EBI, Israel, Japan]
Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J., Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
"Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.";
Nat. Genet. 9:321-328(1995).
[14]
VARIANT HYPOCHONDROPLASIA LYS-540.
DOI=10.1038/ng0795-357; PubMed=7670477 [NCBI, ExPASy, EBI, Israel, Japan]
Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I., Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
"A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.";
Nat. Genet. 10:357-359(1995).
[15]
VARIANT CAN GLU-391.
DOI=10.1038/ng1295-462; PubMed=7493034 [NCBI, ExPASy, EBI, Israel, Japan]
Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
"Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.";
Nat. Genet. 11:462-464(1995).
[16]
CHARACTERIZATION OF VARIANT ACH ARG-380.
PubMed=8599935 [NCBI, ExPASy, EBI, Israel, Japan]
Webster M.K., Donoghue D.J.;
"Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.";
EMBO J. 15:520-527(1996).
[17]
VARIANTS TD CYS-248; CYS-249; CYS-370 AND CYS-373.
DOI=10.1093/hmg/5.4.509; PubMed=8845844 [NCBI, ExPASy, EBI, Israel, Japan]
Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L., le Merrer M., Munnich A., Bonaventure J.;
"Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).";
Hum. Mol. Genet. 5:509-512(1996).
[18]
VARIANT MNKS ARG-250.
PubMed=9042914 [NCBI, ExPASy, EBI, Israel, Japan]
Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K., Whitaker L.A., Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J., Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A., Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M. Jr., Bellus G.A., Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
"A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome.";
Am. J. Hum. Genet. 60:555-564(1997).
[19]
INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND MET-650.
DOI=10.1038/ng0797-260; PubMed=9207791 [NCBI, ExPASy, EBI, Israel, Japan]
Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M., Bergsagel P.L.;
"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.";
Nat. Genet. 16:260-264(1997).
[20]
VARIANT TD CYS-370.
PubMed=9790257 [NCBI, ExPASy, EBI, Israel, Japan]
Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A., Nimura A., Horikawa R., Tanaka T.;
"G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.";
Endocr. J. 45:S171-S174(1998).
[21]
VARIANT HYPOCHONDROPLASIA VAL-538.
DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU17>3.3.CO;2-A; PubMed=10215410 [NCBI, ExPASy, EBI, Israel, Japan]
Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E., Anvret M.;
"A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia.";
Hum. Mutat. 11:333-333(1998).
[22]
VARIANT HYPOCHONDROPLASIA THR-540.
PubMed=9452043 [NCBI, ExPASy, EBI, Israel, Japan]
Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M., Bakker E.;
"Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia.";
Hum. Mutat. Suppl. 1:S62-S65(1998).
[23]
VARIANT TD MET-650.
PubMed=10671061 [NCBI, ExPASy, EBI, Israel, Japan]
Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
"Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia type I.";
Hum. Mutat. 12:362-363(1998).
[24]
VARIANT ARG-250.
DOI=10.1016/S0140-6736(98)24012-8; PubMed=9525367 [NCBI, ExPASy, EBI, Israel, Japan]
Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J., Mulley J.C.;
"Deafness due to Pro250Arg mutation of FGFR3.";
Lancet 351:877-878(1998).
[25]
VARIANTS PLSD-SD CYS-248; CYS-249 AND CYS-373.
DOI=10.1002/(SICI)1096-8628(19990611)84:5<476::AID-AJMG12>3.3.CO;2-O; PubMed=10360402 [NCBI, ExPASy, EBI, Israel, Japan]
Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B., Wilcox W.R.;
"Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.";
Am. J. Med. Genet. 84:476-480(1999).
[26]
VARIANT MNKS ARG-250.
PubMed=9950359 [NCBI, ExPASy, EBI, Israel, Japan]
Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J., Renier D.;
"Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation.";
J. Med. Genet. 36:9-13(1999).
[27]
VARIANTS BLADDER AND CERVIX CANCERS CYS-248; CYS-249; CYS-370 AND GLU-650.
DOI=10.1038/12615; PubMed=10471491 [NCBI, ExPASy, EBI, Israel, Japan]
Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.";
Nat. Genet. 23:18-20(1999).
[28]
VARIANT HYPOCHONDROPLASIA GLN-650.
DOI=10.1086/316892; PubMed=11055896 [NCBI, ExPASy, EBI, Israel, Japan]
Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T., Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J., Francomano C.A.;
"Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.";
Am. J. Hum. Genet. 67:1411-1421(2000).
[29]
VARIANT HYPOCHONDROPLASIA SER-540.
DOI=10.1136/jmg.37.3.220; PubMed=10777366 [NCBI, ExPASy, EBI, Israel, Japan]
Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G., De Paepe A.;
"Clinical and radiographic features of a family with hypochondroplasia owing to a novel asn540ser mutation in the fibroblast growth factor receptor 3 gene.";
J. Med. Genet. 37:220-224(2000).
[30]
VARIANT MNKS ARG-250.
DOI=10.1002/ajmg.10049; PubMed=11746040 [NCBI, ExPASy, EBI, Israel, Japan]
Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
"Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel shoulder with and without Pro250Arg mutation in the FGFR3 gene.";
Am. J. Med. Genet. 104:112-119(2001).
[31]
INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
DOI=10.1046/j.1365-2141.2001.02957.x; PubMed=11529856 [NCBI, ExPASy, EBI, Israel, Japan]
Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T., Neri A.;
"Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).";
Br. J. Haematol. 114:362-364(2001).
[32]
VARIANT COLORECTAL CANCER LYS-322.
PubMed=11325814 [NCBI, ExPASy, EBI, Israel, Japan]
Jang J.-H., Shin K.-H., Park J.-G.;
"Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.";
Cancer Res. 61:3541-3543(2001).
[33]
VARIANT BLADDER CANCER GLN-650.
DOI=10.1038/sj.onc.1204110; PubMed=11314002 [NCBI, ExPASy, EBI, Israel, Japan]
Sibley K., Cuthbert-Heavens D., Knowles M.A.;
"Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.";
Oncogene 20:686-691(2001).
[34]
VARIANT HYPOCHONDROPLASIA SER-540.
DOI=10.1002/ajmg.a.10238; PubMed=12707965 [NCBI, ExPASy, EBI, Israel, Japan]
Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V., Francois C., Huet F., Couailler J.-F., Campos-Xavier A.B., Bonaventure J., Le Merrer M.;
"Hlypochondroplasia and stature within normal limits: another family with an Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene.";
Am. J. Med. Genet. A 119:81-84(2003).
[35]
VARIANT CATSHL SYNDROME HIS-621.
DOI=10.1086/508433; PubMed=17033969 [NCBI, ExPASy, EBI, Israel, Japan]
Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A., Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C., Bamshad M.J.;
"A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.";
Am. J. Hum. Genet. 79:935-941(2006).
[36]
VARIANTS KERATINOCYTIC NON-EPIDERMOLYTIC NEVUS CYS-248; CYS-370 AND ARG-380.
DOI=10.1172/JCI28163; PubMed=16841094 [NCBI, ExPASy, EBI, Israel, Japan]
Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A.;
"Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.";
J. Clin. Invest. 116:2201-2207(2006).
[37]
VARIANT LADDS ASN-513.
DOI=10.1038/ng1757; PubMed=16501574 [NCBI, ExPASy, EBI, Israel, Japan]
Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.;
"Mutations in different components of FGF signaling in LADD syndrome.";
Nat. Genet. 38:414-417(2006).
[38]
VARIANT CAN GLU-391.
DOI=10.1111/j.1399-0004.2007.00884.x; PubMed=17935505 [NCBI, ExPASy, EBI, Israel, Japan]
Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
"Crouzon with acanthosis nigricans. Further delineation of the syndrome.";
Clin. Genet. 72:405-410(2007).
[39]
VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646 AND GLU-650.
DOI=10.1038/nature05610; PubMed=17344846 [NCBI, ExPASy, EBI, Israel, Japan]
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
"Patterns of somatic mutation in human cancer genomes.";
Nature 446:153-158(2007).
Comments
  • FUNCTION: Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.
  • CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
  • INTERACTION:
    Self; NbExp=1; IntAct=EBI-348399, EBI-348399;
    P05230:FGF1; NbExp=2; IntAct=EBI-348399, EBI-698068;
    Q9Y4H4:GPSM3; NbExp=1; IntAct=EBI-348399, EBI-347538;
  • SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
  • ALTERNATIVE PRODUCTS: 3 named isoforms [FASTA] produced by alternative splicing.
    Name1
    SynonymsIIIc
    Isoform IDP22607-1
    This is the isoform sequence displayed in this entry.
    Name2
    SynonymsIIIb
    Isoform IDP22607-2
    Features which should be applied to build the isoform sequence: VSP_002988.
    Name3
    Isoform IDP22607-3
    Features which should be applied to build the isoform sequence: VSP_002989.
  • TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Epithelial cells show exclusively isoform 2 transcripts while fibroblastic cells show a mixture of isoform 1 and isoform 2.
  • DISEASE: Defects in FGFR3 are the cause of achondroplasia (ACH) [MIM:100800]. ACH is an autosomal dominant disease and is the most frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.
  • DISEASE: Defects in FGFR3 are the cause of Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independant disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosonal dominant mode of inheritance.
  • DISEASE: Defects in FGFR3 are the cause of platyspondylic lethal skeletal dysplasia Sand Diego type (PLSD-SD) [MIM:270230]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-SD is characterized by postnatal growth deficiency, mild developmental delay, short trunk, craniofacial abnormalities, platyspondyly, delayed ossification, generalized osteoporosis and thin ribs.
  • DISEASE: Defects in FGFR3 are a cause of thanatophoric dysplasia (TD) [MIM:187600, 187601]; also known as thanatophoric dwarfism. TD is the most common neonatal lethal skeletal dysplasia. Affected individuals display features similar to those seen in homozygous achondroplasia. It causes severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. In the most common subtype, TD1, femur are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.
  • DISEASE: Defects in FGFR3 are a cause of hypochondroplasia (HCH) [MIM:146000]. HCH is an autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.
  • DISEASE: Defects in FGFR3 are a cause of bladder cancer [MIM:109800]. Somatic mutations can constitutively activate FGFR3.
  • DISEASE: Defects in FGFR3 are a cause of cervical cancer [MIM:603956].
  • DISEASE: Defects in FGFR3 are the cause of camptodactyly tall stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474]. CATSHL syndrome is an autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.
  • DISEASE: A chromosomal aberration involving FGFR3 may be a cause of multiple myeloma (MM) [MIM:254500]. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.
  • DISEASE: Defects in FGFR3 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
  • DISEASE: Defects in FGFR3 are a cause of keratinocytic non-epidermolytic nevus [MIM:162900]; also called pigmented moles. Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.
  • DISEASE: Defects in FGFR3 are a cause of Muenke syndrome (MNKS) [MIM:602849]; also known as Muenke non-syndromic coronal craniosynostosis. MNKS is a condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.
  • SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
  • SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
  • SIMILARITY: Contains 1 protein kinase domain.
  • WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/FGFR99.html";.
  • WEB RESOURCE: Name=GeneReviews; URL="http://www.genetests.org/query?gene=FGFR3";.
  • WEB RESOURCE: Name=NIEHS-SNPs; URL="http://egp.gs.washington.edu/data/fgfr3/";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
M58051; AAA52450.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF245114; AAF63380.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY768549; AAU89726.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M64347; AAA58470.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M59374; AAA63209.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
S76733; AAB33323.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X84939; CAA59334.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
U22410; AAA67781.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
IPI IPI00027174; -.
IPI00220253; -.
IPI00220254; -.
PIR A38576; TVHUF3.
RefSeq NP_000133.1; -.
UniGene Hs.1420
3D structure databases
PDB
1RY7; X-ray; 3.20 A; B=33-365.[ExPASy / RCSB / EBI]
PDBsum 1RY7; -.
SMR P22607; 458-755.
ModBase P22607.
Protein-protein interaction databases
DIP DIP:4016N; -.
IntAct P22607; 22.
PTM databases
PhosphoSite P22607; -.
Enzyme and pathway databases
BRENDA 2.7.10.1; 247.
Pathway_Interaction_DB fgf_pathway; FGF signaling pathway.
Reactome REACT_9470; Signaling by FGFR.
Organism-specific databases
GeneCards GC04P001762; -.
H-InvDB HIX0031383; -.
HGNC HGNC:3690; FGFR3.
GenAtlas FGFR3.
HPA CAB004231; -.
MIM 100800; phenotype. [NCBI / EBI]
109800; phenotype. [NCBI / EBI]
134934; gene. [NCBI / EBI]
146000; phenotype. [NCBI / EBI]
149730; phenotype. [NCBI / EBI]
162900; phenotype. [NCBI / EBI]
187600; phenotype. [NCBI / EBI]
187601; phenotype. [NCBI / EBI]
254500; phenotype. [NCBI / EBI]
270230; phenotype. [NCBI / EBI]
602849; phenotype. [NCBI / EBI]
603956; phenotype. [NCBI / EBI]
610474; phenotype. [NCBI / EBI]
612247; phenotype. [NCBI / EBI]
Orphanet 15; Achondroplasia.
85164; Camptodactyly - tall stature - scoliosis - hearing loss.
93262; Crouzon syndrome - acanthosis nigricans.
1555; Cutis gyrata - acanthosis nigricans - craniosynostosis.
429; Hypochondroplasia.
35099; Isolated brachycephaly.
2343; Isolated cloverleaf skull syndrome.
35098; Isolated plagiocephaly.
2363; Lacrimo-auriculo-dento-digital syndrome.
53271; Muenke syndrome.
794; Saethre-Chotzen syndrome.
85165; Severe achondroplasia - developmental delay - acanthosis nigricans.
2655; Thanatophoric dwarfism.
PharmGKB PA28129; -.
Gene expression databases
ArrayExpress P22607; -.
Bgee P22607; -.
CleanEx HS_FGFR3; -.
GermOnline ENSG00000068078; Homo sapiens.
Ontologies
GO
GO:0005887; Cellular component: integral to plasma membrane (traceable author statement from ProtInc).
GO:0005524; Molecular function: ATP binding (inferred from electronic annotation from UniProtKB-KW).
GO:0005007; Molecular function: fibroblast growth factor receptor activity (non-traceable author statement from UniProtKB).
GO:0042802; Molecular function: identical protein binding (inferred from physical interaction from IntAct).
GO:0016049; Biological process: cell growth (non-traceable author statement from UniProtKB).
GO:0008543; Biological process: fibroblast growth factor receptor signaling pathway (traceable author statement from ProtInc).
GO:0007259; Biological process: JAK-STAT cascade (traceable author statement from ProtInc).
GO:0000165; Biological process: MAPKKK cascade (traceable author statement from ProtInc).
GO:0006468; Biological process: protein amino acid phosphorylation (inferred from electronic annotation from InterPro).
GO:0007605; Biological process: sensory perception of sound (inferred from electronic annotation from UniProtKB-KW).
GO:0001501; Biological process: skeletal system development (traceable author statement from ProtInc).
QuickGo view.
Family and domain databases
InterPro IPR016248; Fibroblast_GF_rcpt.
IPR013151; Ig.
IPR007110; Ig-like.
IPR013783; Ig-like_fold.
IPR013098; Ig_I-set.
IPR003599; Ig_sub.
IPR003598; Ig_sub2.
IPR000719; Prot_kinase_core.
IPR017441; Protein_kinase_ATP_BS.
IPR001245; Tyr_pkinase.
IPR008266; Tyr_pkinase_AS.
Graphical view of domain structure.
Gene3D G3DSA:2.60.40.10; Ig-like_fold; 3.
Pfam PF07679; I-set; 1.
PF00047; ig; 2.
PF07714; Pkinase_Tyr; 1.
Pfam graphical view of domain structure.
PIRSF PIRSF000628; FGFR; 1.
PRINTS PR00109; TYRKINASE.
ProDom PD000001; Prot_kinase; 1.
[Domain structure / List of seq. sharing at least 1 domain]
SMART SM00409; IG; 1.
SM00408; IGc2; 2.
SM00219; TyrKc; 1.
SMART graphical view of domain structure.
PROSITE PS50835; IG_LIKE; 3.
PS00107; PROTEIN_KINASE_ATP; 1.
PS50011; PROTEIN_KINASE_DOM; 1.
PS00109; PROTEIN_KINASE_TYR; 1.
PROSITE graphical view of domain structure (profiles).
Proteomic databases
PRIDE P22607; -.
Genome annotation databases
Ensembl ENSG00000068078; Homo sapiens. [Contig view]
GeneID 2261; -.
KEGG hsa:2261; -.
Phylogenomic databases
HOVERGEN P22607; -.
Other
DrugBank DB00039; Palifermin.
NextBio 9179; -.
SOURCE FGFR3; Homo sapiens.
ProtoNet P22607.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Alternative splicing; ATP-binding; Chromosomal rearrangement; Craniosynostosis; Deafness; Disease mutation; Disulfide bond; Dwarfism; Ectodermal dysplasia; Glycoprotein; Immunoglobulin domain; Kinase; Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat; Signal; Transferase; Transmembrane; Tyrosine-protein kinase.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
SIGNAL   1    22  22      
CHAIN   23   806  784     Fibroblast growth factor receptor 3. PRO_0000016785
TOPO_DOM   23   375  353     Extracellular (Potential). 
TRANSMEM   376   396  21     Potential. 
TOPO_DOM   397   806  410     Cytoplasmic (Potential). 
DOMAIN   24   126  103     Ig-like C2-type 1. 
DOMAIN   151   244  94     Ig-like C2-type 2. 
DOMAIN   253   355  103     Ig-like C2-type 3. 
DOMAIN   472   761  290     Protein kinase. 
NP_BIND   478   486  9     ATP (By similarity). 
ACT_SITE   617   617        Proton acceptor (By similarity). 
BINDING   508   508        ATP (By similarity). 
MOD_RES   647   647        Phosphotyrosine (By similarity). 
MOD_RES   648   648        Phosphotyrosine; by autocatalysis (By similarity). 
CARBOHYD   98    98        N-linked (GlcNAc...) (Potential). 
CARBOHYD   225   225        N-linked (GlcNAc...) (Potential). 
CARBOHYD   262   262        N-linked (GlcNAc...) (Potential). 
CARBOHYD   294   294        N-linked (GlcNAc...) (Potential). 
CARBOHYD   315   315        N-linked (GlcNAc...) (Potential). 
CARBOHYD   328   328        N-linked (GlcNAc...) (Potential). 
DISULFID   61   109        Potential. 
DISULFID   176   228        Potential. 
DISULFID   275   339        Potential. 
VAR_SEQ   311   422        Missing (in isoform 3). VSP_002989
VAR_SEQ   311   358        TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHH SAWLVVLP -> SWISESVEADVRLRLANVSERDGGEYLCRATNFIGVAEKA FWLSVHGPRA (in isoform 2). VSP_002988
VARIANT   65    65  1     G -> R (in dbSNP:rs2305178 [NCBI]). VAR_022167 
VARIANT   79    79  1     T -> S (in a lung adenocarcinoma sample; somatic mutation). VAR_042207 
VARIANT   228   228  1     C -> R (in a colorectal adenocarcinoma sample; somatic mutation). VAR_042208 
VARIANT   248   248  1     R -> C (in bladder cancer, PLSD-SD, keratinocytic non-epidermolytic nevus and TD; severe and lethal; also found as somatic mutation in one patient with multiple myeloma). VAR_004148 
VARIANT   249   249  1     S -> C (in bladder cancer, cervical cancer, PLSD-SD and TD; type 1). VAR_004149 
VARIANT   250   250  1     P -> R (in MNKS; also some individuals with autosomal dominant congenital sensorineural deafness without craniosynostosis; dbSNP:rs4647924 [NCBI]). VAR_004150 
VARIANT   322   322  1     E -> K (in colorectal cancer). VAR_018388 
VARIANT   338   338  1     T -> M. VAR_042209 
VARIANT   370   370  1     G -> C (in bladder cancer, keratinocytic non-epidermolytic nevus and TD; type 1). VAR_004151 
VARIANT   371   371  1     S -> C (in TD; type 1). VAR_004152 
VARIANT   373   373  1     Y -> C (in PLSD-SD and TD; type 1). VAR_004153 
VARIANT   375   375  1     G -> C (in ACH). VAR_004154 
VARIANT   380   380  1     G -> R (in keratinocytic non-epidermolytic nevus and ACH; results in constitutive activation; very common mutation; dbSNP:rs28931614 [NCBI]). VAR_004155 
VARIANT   384   384  1     F -> L (in dbSNP:rs17881656 [NCBI]). VAR_022168 
VARIANT   391   391  1     A -> E (in CAN; dbSNP:rs28931615 [NCBI]). VAR_004156 
VARIANT   441   441  1     A -> T (in dbSNP:rs17884368 [NCBI]). VAR_022169 
VARIANT   513   513  1     D -> N (in LADDS). VAR_029887 [3D]
VARIANT   538   538  1     I -> V (in hypochondroplasia). VAR_004157 [3D]
VARIANT   540   540  1     N -> K (in hypochondroplasia). VAR_004158 [3D]
VARIANT   540   540  1     N -> S (in hypochondroplasia; mild). VAR_018389 [3D]
VARIANT   540   540  1     N -> T (in hypochondroplasia). VAR_004159 [3D]
VARIANT   621   621  1     R -> H (in CATSHL syndrome). VAR_029108 [3D]
VARIANT   646   646  1     D -> N. VAR_042210 [3D]
VARIANT   650   650  1     K -> E (in TD and bladder cancer samples; bladder transitional cell carcinoma; somatic mutation). VAR_004160 [3D]
VARIANT   650   650  1     K -> M (in ACH and TD; type 1). VAR_004161 [3D]
VARIANT   650   650  1     K -> Q (in hypochondroplasia and bladder cancer; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations). VAR_018390 [3D]
VARIANT   717   717  1     A -> T (in dbSNP:rs17882190 [NCBI]). VAR_022170 [3D]
VARIANT   726   726  1     I -> F (in dbSNP:rs17880763 [NCBI]). VAR_022171 [3D]
CONFLICT   395   395        L -> V (in Ref. 4; AAA58470). 
STRAND   163   167  5      
STRAND   172   175  4      
STRAND   185   187  3      
TURN   208   211  4      
STRAND   212   215  4      
HELIX   220   222  3      
STRAND   226   232  7      
STRAND   235   246  12      
STRAND   263   268  6      
STRAND   271   273  3      
STRAND   283   289  7      
HELIX   293   295  3      
STRAND   302   304  3      
STRAND   324   326  3      
STRAND   335   345  11      
STRAND   348   357  10      
Sequence information
Length: 806 AA [This is the length of the unprocessed precursor] Molecular weight: 87710 Da [This is the MW of the unprocessed precursor] CRC64: BC5EA75EA46F447E [This is a checksum on the sequence]
        10         20         30         40         50         60 
MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS 

        70         80         90        100        110        120 
CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH 

       130        140        150        160        170        180 
FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG 

       190        200        210        220        230        240 
NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT 

       250        260        270        280        290        300 
YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP 

       310        320        330        340        350        360 
DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE 

       370        380        390        400        410        420 
EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK 

       430        440        450        460        470        480 
RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE 

       490        500        510        520        530        540 
GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN 

       550        560        570        580        590        600 
LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ 

       610        620        630        640        650        660 
VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW 

       670        680        690        700        710        720 
MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT 

       730        740        750        760        770        780 
HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS 

       790        800 
SSSGDDSVFA HDLLPPAPPS SGGSRT 

P22607 in FASTA format

View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

BLAST logo BLAST submission on ExPASy/SIB
or at NCBI (USA)
Tools Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
PROSITE logo ScanProsite, MotifScan SWISS-MODEL Submit a homology modeling request to SWISS-MODEL
NPSA logo NPSA Sequence analysis tools

ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
 Hosted by ca flag CBR Canada Mirror sites: Australia  Brazil  China  Korea  Switzerland
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!